Subscribe
Conference Correspondent

ASCEND-3: a Phase 2 Study of Ceritinib in ALK Inhibitor-Naïve Adult Patients with ALK+ NSCLC

Conference Correspondent - ASCO 2015 - Lung Cancer

The ALK inhibitor crizotinib is more effective that first- or second-line chemotherapy in patients with advanced ALK plus NSCLC.a Thus, targeting ALK is a valid approach in patients with ALK plus NSCLC. Ceritinib, a second-generation, oral ALK inhibitor, demonstrated clinical activity in advanced ALK inhibitor (ALKi)-pretreated and -naïve patients with ALK plus NSCLC, including those with brain metastases.b Felip and colleaguesc now presented results from ASCEND-3, a single-arm, open-label, multicenter, phase 2 study which evaluated efficacy and safety of ceritinib in ALKi-naïve patients. At the time of presentation, 124 patients had enrolled worldwide and received oral ceritinib 750 mg/d. Investigators assessed whole body (WB) and intracranial (I) responses. Prior chemotherapy (≤3 lines) was permitted. The median time from initial diagnosis to treatment start was 13.5 (1.0–283.1) months; median exposure duration was 8.0 (0.1–16.2) months; median follow-up (range) was 8.3 (0.6-16.3) months. The primary endpoint of the study was overall response rate (ORR) by RECIST criteria, with secondary objectives including duration of response (DOR), safety, progression-free survival (PFS), overall survival (OS), and patient-reported outcomes (PRO).

The study met its primary endpoint, with a WB ORR of 63.7%. Investigator-assessed efficacy outcomes are shown in the Table. At baseline, 10 patients had investigator-assessed measurable brain lesions (MBL); Intracranial Disease Control Rate (IDCR) was 80.0% (95% CI: 44.4, 97.5); in 6 patients with MBL and no prior brain radiation therapy (BRT), all responses in the brain matched or exceeded the WB response. The median time to first response was 1.8 months, and for patients with measurable baseline disease, 93.9% had a decrease in tumor burden from baseline. The most common adverse events (AEs; mostly Grade 1/2) were diarrhea, nausea, and vomiting, and 7.3% of the patients discontinued treatment due to AEs, with 73% requiring dose adjustment or interruption. Serious AEs were reported in 22% of patients, including pericarditis. PRO included symptom improvement in 82% of treated patients and stable global quality of life scores. This study demonstrates that ceritinib achieved a robust ORR and promising DOR and PFS in ALKi-naïve patients with advanced NSCLC, with and without baseline brain metastases. Indeed, ceritinib showed brain responses even in those patients with no prior BRT. Safety outcomes were similar to those observed in the ASCEND-1 trial.a

Click table to enlarge

  1. Shaw AT, et al. N Engl J Med. 2013;368:2385-2394.
  2. Kim D-W, et al. ASCO 2014. Abstract 8003^.
  3. Felip E, et al. ASCO 2015. Abstract 8060.
Related Items
Afatinib vs Erlotinib as Second-line Therapy of Patients with Advanced Squamous Cell Carcinoma (SCC) of the Lung: Analysis from the LUX-Lung 8 Trial
Conference Correspondent published on May 31, 2015 in ASCO 2015 - Lung Cancer
Final Follow-up Results from RADIANT: Adjuvant Erlotinib Vs Placebo Following Complete Tumor Resection in Patients with Stage IB–IIIA EGFR-positive NSCLC
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
GASTO 1001: a Phase 2 Trial of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin in Patients with Unresectable Stage III Lung Adenocarcinoma
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Efficacy and Safety of BCD-021, a Bevacizumab Biosimilar Candidate, Compared to Avastin® in Patients with Advanced Nonsquamous NSCLC
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
PD-L1, PD-1, and CTLA-4 as Prognostic Biomarkers in Resected NSCLC
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
First-line Monotherapy with Nivolumab in Advanced NSCLC: Safety, Efficacy, and Correlation of Outcomes with PD-L1 Expression
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Results from the GENIUS Trial: Maintenance Therapy with Gefitinib/Pemetrexed vs Pemetrexed for Metastatic Lung Adenocarcinoma with No Sensitizing EGFR Mutation
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Subgroup Analysis from REVEL: Safety by Histology and Efficacy in Nonsquamous NSCLC
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Docetaxel plus Ramucirumab vs Docetaxel plus Placebo as Second-line Treatment for Advanced NSCLC: a Phase 2 Multicenter Trial in Japan
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Results from the REVEL Trial: Exposure-Response Relationship for Ramucirumab plus Docetaxel vs Docetaxel as Second-line Treatment of Metastatic NSCLC
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Last modified: December 16, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology